Glencoe Software Inc., a world-leader in image data management platforms for the research, biopharma and publication industries, is pleased to announce the completion of its Seed Investment Round, in partnership with TAGS (TIE Angels Group Seattle), several Seattle area angel investors, and Glencoe Friends and Family. This Seed Round has raised over $800,000 to support Glencoe Software’s go-to market strategy for the digital pathology sector. With strong OEM partnerships and direct customer installs in High Content Screening labs in research and biopharma, Glencoe Software now aims to bring its world-class image data management and analysis products to the rapidly growing digital pathology market. The Seed Round investment provides support for the development of a sales and marketing team and increased product development focused on this high-growth opportunity.
Glencoe Software’s business model is based on world-class, open source technology. Its OMERO Data Management Engine and Bio-Formats data access tool are used in thousands of institutions worldwide under open source licenses. Since 2005, Glencoe Software has exclusively provided commercially licensed installations of this software platform, for example Harvard Medical School’s LINCS Database. This unique partnership between open source technology and commercial delivery of world class technology and services has been a key success driver for Glencoe Software.
Dr Jason Swedlow, CEO of Glencoe Software, said, “The completion of this Seed Round with TAGS, Seattle area angels, and our Friends & Family investors is another exciting step in Glencoe Software’s progression. The entire Glencoe team is very excited to be moving aggressively into digital pathology and we are ready to deploy our new product and capabilities to this new market segment very quickly. Our OMERO platform and Bio-Formats tools are ideally suited for managing large whole slide image datasets and integrating them with LIMS, ELN or analysis toolboxes from any organization.”